EDGAR Filing Documents for 0001683168-18-001713

Form 1-A - Offering Statement [Regulation A]:

SEC Accession No. 0001683168-18-001713

Filing Date

2018-06-15

Accepted

2018-06-15 17:22:04

Documents

Document Format Files

Seq	Description	Document	Type	Size
1		primary_doc.html	1-A
1		primary_doc.xml	1-A	15028
2	PRELIMINARY OFFERING STATEMENT	cns_1a-poc.htm	PART II AND III	771289
3	FORM OF CONVERTIBLE PROMISSORY NOTE	cns_a1-ex0301.htm	EX1A-3 HLDRS RTS	29230
4	FORM OF COMMON STOCK PURCHASE WARRANT	cns_a1-ex0302.htm	EX1A-3 HLDRS RTS	83128
5	FORM OF SAFE AGREEMENT	cns_a1-ex0303.htm	EX1A-3 HLDRS RTS	63284
6	AMENDED AND RESTATED PATENT LICENSE AGREEMENT	cns_a1-ex0601.htm	EX1A-6 MAT CTRCT	106882
7	COLLABORATION AND ASSET PURCHASE AGREEMENT	cns_a1-ex0602.htm	EX1A-6 MAT CTRCT	117495
8	2017 STOCK PLAN	cns_a1-ex0603.htm	EX1A-6 MAT CTRCT	101213
9	EMPLOYMENT AGREEMENT BETWEEN CNS PHARMACEUTICALS, INC. AND JOHN M. CLIMACO	cns_a1-ex0604.htm	EX1A-6 MAT CTRCT	62427
10	CONSULTING AGREEMENT	cns_a1-ex0605.htm	EX1A-6 MAT CTRCT	25593
11	CONSENT	cns_a1-ex1101.htm	EX1A-11 CONSENT	1770
	Complete submission text file	0001683168-18-001713.txt		1378427

Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027

Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701

CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)